JonesResearch analyst Justin Walsh downgraded BioLineRx (BLRX) to Hold from Buy without a price target following the Q4 report. BioLineRx is on “sounder financial footing” following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company’s pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLRX:
- BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress
- BioLineRx Earnings Call: Strategic Shifts and Growth
- BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split
- BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements
- Options Volatility and Implied Earnings Moves Today, March 31, 2025